|Bid||0.0000 x 1800|
|Ask||0.0000 x 1800|
|Day's Range||2.7004 - 2.8000|
|52 Week Range||2.2300 - 10.6600|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||6.37|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ORGO
Good afternoon, ladies and gentlemen, and welcome to the third quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated Including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A risk factors of the company's most recent annual report and its subsequently files quarterly report.
CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared
As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...